News Center

Home page

Peak Report

News reports

Pro 2014-020 (Framework Agreement on Jianfeng Group's Acquisition of Nestor)

Release time:

2020-08-05

Securities Code: 600668 Securities Short Name: Jianfeng Group Announcement No.: 2014-020

Bond Short Name: 13 Jianfeng 01 Bond Code: 122227

Zhejiang Jianfeng Group Co., Ltd.

Reminder Announcement on the Signing of Equity Transfer Framework Agreement by Subsidiaries

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.

Important Content Reminder:

l Transaction Brief Content: Zhejiang Jianfeng Pharmaceutical Co., Ltd., the company's holding subsidiary, recently signed the "Framework Agreement on Equity Transfer of Zhejiang Neshikang Pharmaceutical Co., Ltd." with Creative Medicine and Xi 'an Zizhitong Investment Co., Ltd. to transfer 70% and 25% of the equity of Zhejiang Neshikang Pharmaceutical Co., Ltd.

l This transaction does not constitute a related party transaction

l This transaction does not constitute a major asset reorganization

l There are no major legal obstacles to the implementation of the transaction

l This is a framework agreement, which is the preliminary result of the preliminary negotiations, and the follow-up work has been arranged. The specific matters of equity acquisition need to be further negotiated according to the results of audit, evaluation and due diligence. The formal equity transfer agreement will also be submitted to the company's board of directors or general meeting of shareholders for approval in accordance with the "Stock Listing Rules", the company's articles of association, etc., before it can take effect. There is uncertainty as to whether the equity acquisition will be realized.

Overview of 1. Transaction

Basic Information of (I) Transaction

Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), the controlling subsidiary of the Company, plans to acquire 70% equity of Zhejiang Neisikang Pharmaceutical Co., Ltd. (hereinafter referred to as "Neisikang Pharmaceutical") held by Creative Medicine (hereinafter referred to as "CM Company") and Xi 'an Zizhitong Investment Co., Ltd. The company (hereinafter referred to as "Zizhitong Company") holds a 25% stake in Nesikang Pharmaceuticals, the total of the two is 95% equity.

(II) company approval.

This is a framework agreement. The specific matters of the equity acquisition need to be further negotiated and negotiated based on due diligence, audit or evaluation results, and will be in accordance with the provisions of the Stock Listing Rules, the company's articles of association, etc. It can be implemented after being submitted to the company's board of directors or shareholders meeting for approval. There is the possibility of changes in the implementation and implementation process of the framework agreement.

This equity transfer does not involve connected transactions, nor does it constitute a major asset reorganization as stipulated in the Measures for the Administration of Major Asset Reorganization of Listed Companies.

Basic Information of 2. Counterparty

(I) Creative Medicine

, Enterprise Name: Creative Medicine

2, Enterprise Nature: Limited Liability Company

3, Place of Registration: Cayman

, Main Office Location: 190 Elgin Street, Grand Cayman, Cayman Islands, ( KY1-9005)

, Legal Representative: Yang Zhi

, Paid-in Capital: US $13.5 million

7, Main Business: Investment and Investment Management

, Major Shareholder or Actual Controller: bioVeda China Fund II L.P.;New Enterprise Associates 13,Limited Partnership;Yifang Technology Group, Ltd.

9, 2013 main financial indicators: total assets of $41.0119 million, net assets of $13.3334 million, net profit of-$2800.

(II) Xi' an zizhitong investment co., ltd.

1, enterprise name: Xi' an zizhitong investment co., ltd.

2, enterprise nature: limited liability company (natural person investment or holding)

3, place of registration:

4 on the east side of the 10th floor of Zhongsheng Building, 69 Jinye Road, Xi 'an High-tech Zone, main office location:

5 on the east side of the 10th floor of Zhongsheng Building, 69 Jinye Road, Xi 'an High-tech Zone, legal representative: Zhang Hua

6, registered capital: 100 million yuan

7, main business: industrial investment and venture investment; asset management (excluding financial services), investment management and consulting.

8, major shareholder or actual controller: Zhang Hua

9, main financial indicators for 2013 (RMB): total assets of 257.0996 million yuan, net assets of 104.9223 million yuan, net profit of -5.3861 million yuan.

Basic Information of 3. Transaction Target

1, Target Name: 95 Equity of Zhejiang Nesikang Pharmaceutical Co., Ltd.;

2, major shareholder: CM Company holds 70% equity; Zizhitong Company holds 25% equity; zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. holds a 5% stake;

3, legal representative: Yang Zhi;

4, main business: drug bulk drug production; The main products are karat , azithromycin , fenofibrate, etc.

5, registered capital: US $36.10667 million;

6, Company Type: Limited Liability Company (Sino-foreign Joint Venture)

7, Establishment Date: December 23, 2002;

8, place of registration: 1318 Jinsha Street, Linjiang Industrial Zone, Wucheng District, Jinhua City;

9, Nesikang Pharmaceutical's 2013 financial report was audited by Jinhua Zhongjian Joint Accounting Firm, with main financial indicators:

Project (RMB 10,000)	at the end of 2013
Total Assets	43625.72
Total Liabilities	26889.44
Net Assets	16736.28
	2013
Operating Income	28776.51
Net Profit	435.01

The company will entrust an audit institution with securities and futures business qualifications to carry out necessary audit on the financial statements of Neisikang Pharmaceutical, the audit results may differ from the above financial data. Main Contents of

4. Framework Agreement

"Party A": Zhejiang Jianfeng Pharmaceutical Co., Ltd.

"Party B": creative Medicine and Xi' an zizhitong investment co., ltd.

(I) equity transfer, price payment

1.CM company jointly transferred its 70% equity of nesikang pharmaceutical and zizhitong company its 25% equity of nesikang pharmaceutical to party a.

2, A and B agree on the transfer price after considering the audit, evaluation report, market trend and other comprehensive factors that may affect the operation efficiency.

3. The transfer price will be priced in RMB and paid to Party B in installments.

(II) Assets Evaluation

Within 15 working days after the signing of the framework agreement, intermediary agencies with securities qualification such as audit and evaluation hired by Party A and approved by Party B shall conduct a comprehensive audit, evaluation and due diligence on Neisikang Pharmaceutical, and strive to complete the audit, evaluation and due diligence within no more than 30 working days. Naisikang Pharmaceuticals and Party B shall provide the greatest convenience for the audit, evaluation and due diligence work, provide relevant information in a timely manner, and undertake to provide complete and true information required for the audit, evaluation and due diligence work. Otherwise, it will bear the corresponding legal responsibility.

(III) exclusive matters

Unless approved in writing by Party A, within 60 working days after this agreement comes into effect (hereinafter referred to as exclusive period), party B and any representative under its control shall not, directly or indirectly, seek to contact, negotiate, negotiate or sign any agreement or letter of intent with any third party (whether or not such agreement or letter of intent is binding on it) with respect to any matter agreed upon in this Agreement. During the exclusive period, Party B shall ensure the achievement of the transfer conditions, and the Buyer shall draft the equity transfer agreement and other transaction documents for negotiation. The term of this agreement and the exclusive period may be extended with the consent of the parties.

5. the impact and risk tips of this transaction

This equity acquisition is the specific implementation of the company's strategic plan and 2014 business plan. If the equity transfer can be successfully completed, it will expand the scope and scale of the company's pharmaceutical business.

In view of the fact that this framework agreement only determines the basic framework of the transaction, it is still necessary to further reach an equity transfer agreement on the basis of audit, evaluation and due diligence, and submit it to the company's board of directors or shareholders' meeting for consideration. There is uncertainty about whether the transaction can be realized. The company will be based on the progress of the acquisition of the progress of the timely disclosure of the follow-up progress, so that the majority of investors pay attention to investment risks.

hereby announce

Zhejiang Jianfeng Group Co., Ltd.

Board of Directors

July 28, 2014

More information

Peak's "Centennial" Ideal

Editor's note: During the National Day, the "Jinhua New Observation" column of Jinhua TV Station launched a series of reports on "National Day New Observation: New Development of Old Enterprises" to understand the new developments of those old enterprises that have grown up with New China in the new era. October 3 broadcast of the "peak of the 'centennial 'ideal", about the development of the peak group and the future direction of development. The "century" ideal of the peak Jinhua TV reporter Wang Dujuan Jiang Qian host: speaking of Zhejiang Jianfeng Group Co., Ltd., Jinhua people are no stranger. The older generation of Jinhua people are more familiar with, may be the predecessor of Jianfeng Group-Jinhua Cement Factory. Open the first old photo 58 years ago, surrounded by mountains and a rice field in the middle. Old Jinhua can see at a glance that this is the Wise Temple, 8 kilometers north of Jinhua City and east of the former Zhuangtou of Luodian Town. In August 1958, the first group of pioneers came here and built Jinhua's first cement factory on a desolate hillside of 16.94 mu with a pair of hands and warm blood. From the earliest cattle-drawn ball forming machine to the electric ball forming machine, from pure manual labor to machine substitution, it took 26 years of hard work. By 1983, the annual output of peak cement reached 120000 tons, the output value was 6.75 million yuan, and the profit was 2.4 million yuan. In these 26 years, the cement plant has experienced a difficult period of the country, and the ten-year catastrophe of the "Cultural Revolution" has finally ushered in a good time of reform and opening up with tenacious vitality, laying the foundation for steady development in the future. Looking at these old pictures,

2020

07-31

Peak Cement Successfully Enters Lancang Airport Project

News from our newspaper On September 26, the first batch of airport runway cement produced by Yunnan Jianfeng Cement Company was successfully delivered to the Lancang Airport site, which marked another important step in the expansion of Jianfeng Cement in the southwest Yunnan market. Lancang Airport is located in Donghi Town, Lancang Lahu Autonomous County, Pu'er City. It is the center of the "three counties" and "Pu'er Green Triangle" tourist areas of Lancang, Menglian and Ximeng, with a wide range of radiation and obvious location advantages. The project is a national "Twelfth Five-Year Plan" construction project and a key construction project in Yunnan Province. It was approved by the State Council and the Central Military Commission in January 2013. It started construction at the end of November 2014 and is expected to be completed in April 2017. The current project of Lancang Airport is designed to meet the target of 250000 passenger throughput and 750 tons of cargo throughput by 2020, including the construction of a 2600-meter-long and 45-meter-wide runway, the construction of a new 3000-square-meter terminal building and 4 apron parking spaces, including communication, navigation, lighting, meteorology and other supporting projects. The total investment of the project is 1.533 billion yuan. Upon completion, it can be used for Boeing 737 series, Airbus A319 and A320 series, MA-60 and other passenger aircraft take off and land. Since the start of the Lancang Airport project, Yunnan Peak has listed it as an important goal to strive. Compared with ordinary cement, special cement for airport runways has the characteristics of small shrinkage, strong wear resistance, good frost resistance and low alkali content in addition to the requirements of ordinary 42.5 Portland cement. To this end, Yunnan peak in the project to strive for at the same time, the collection of technical forces to tackle the problem, in the clinker composition to determine, cooked.

2020

07-31

Jianfeng won the Zhejiang Industrial Award

A few days ago, we learned from the relevant departments of Zhejiang Province that the company won the 2016 "Zhejiang Industrial Award Silver Award". Zhejiang Industrial Award was established in 2014 and is selected every two years. The purpose of carrying out the selection and commendation of the Zhejiang Industrial Awards is to thoroughly implement the "August 8 Strategy", comprehensively implement the innovation-driven development strategy, speed up the industrial transformation and upgrading with the "four for three" as the starting point, and commend the adherence to the scientific concept of development. adhere to industry, conscientiously fulfill social responsibilities, establish a modern enterprise system, and take a new road of industrialization with characteristics. The evaluation work is jointly organized and implemented by Zhejiang Industrial Economic Federation, Enterprise Federation, Entrepreneur Association, relevant provincial industry associations, municipal industrial economic federations, enterprise federations, entrepreneur associations, and relevant units. The award review committee is composed of relevant government departments, provincial "three committees", relevant provincial industry associations, and experts in industrial economy, management, finance, taxation, quality, environmental protection, safety, technology, and law, the participating enterprises are comprehensively evaluated from the aspects of industry demonstration role, scientific and technological innovation, economic benefits, resource utilization, environmental protection, brand strategy, product quality, production safety, social responsibility, enterprise management, human resources and so on. "The enterprises that have won the Zhejiang Industrial Award this time are all outstanding enterprises that have made significant contributions to the promotion of Zhejiang's economic development; they are all leading enterprises, backbone enterprises, and high-growth enterprises from different industries, representing the scale of Zhejiang's industrial development. The direction and leading spirit represent the highest level of Zhejiang's industrial development." According to the organizers related negative

2020

07-31

Peak Cement Successfully Enters Lancang Airport Project

2020

07-31

Peak Cement Successfully Enters Lancang Airport Project

2020

07-30

Peak two enterprises were commended

On September 23, the launching ceremony of the 2016 Jinhua Zhejiang Shopping Festival and the 2015 Jinhua Honest Enterprise Commendation Conference were held in the urban people's square. Jianfeng Group's Jinhua Jianfeng Pharmacy Chain Co., Ltd. and Zhejiang Jianfeng International Trade Co., Ltd. were commended.

2020

07-31

< 1...55 56 57...61 > 跳转到页